Halbert Hargrove Global Advisors
TAK icon

Halbert Hargrove Global Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-44
Closed -$701 – 660
2026
Q2 		$701 Buy
+44
New +$728 ﹤0.01% 486

Other funds holding TAK

Crossmark Global Holdings
Crossmark Global Holdings Houston, Texas $7.69B AUM 31.68% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
ABC Arbitrage
ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return
Ethic Inc
Ethic Inc New York $8.7B AUM 37.39% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Hantz Financial Services
Hantz Financial Services Southfield, Michigan $7.48B AUM 14.09% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Halbert Hargrove Global Advisors's TAK Position: Q3 2026 in Review

Halbert Hargrove Global Advisors sold out of Takeda Pharmaceutical (TAK) in Q3 2026, closing a stake of 44 shares — an estimated $701 sold.

Halbert Hargrove Global Advisors first reported a position in TAK in Q2 2026 and held it in 1 quarter. The position peaked at $701 in Q2 2026. 214 funds tracked by Wall St. Rank hold TAK as of Q3 2026.

  • Halbert Hargrove Global Advisors reported no remaining Takeda Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 44 Takeda Pharmaceutical shares in Q3 2026, an estimated $701.
  • Halbert Hargrove Global Advisors first reported a position in Takeda Pharmaceutical in Q2 2026 and held it in 1 quarter.
  • Halbert Hargrove Global Advisors's Takeda Pharmaceutical position peaked at $701 in Q2 2026.
  • 214 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.